Monalisa Sub-Q Regulatory Status: A Professional Sourcing Guide

Monalisa Sub-Q is a specific formulation within the Monalisa range of hyaluronic acid dermal fillers, manufactured by Genoss Co., Ltd. Established in South Korea, Genoss specializes in medical devices for the aesthetic field. As a hyaluronic acid dermal filler, Monalisa Sub-Q is designed for professional application, requiring stringent manufacturing and regulatory oversight. Its origin from South Korea places it within a dynamic market known for advanced aesthetic product development.

The primary regulatory authority in South Korea for medical devices is the Ministry of Food and Drug Safety (MFDS), formerly known as the KFDA. Monalisa Sub-Q holds MFDS approval, confirming its compliance with national safety and quality standards for sale within its country of origin. Furthermore, Genoss Co., Ltd. operates under Good Manufacturing Practices (GMP) regulations. These practices ensure that products like Monalisa Sub-Q are consistently produced and controlled according to quality standards, minimizing risks associated with their use in clinical settings.

For market entry into the European Union, the CE Mark is a critical certification for medical devices. Monalisa Sub-Q has obtained CE 2292 certification, indicating conformity with EU health, safety, and environmental protection standards. This allows for its legal distribution within the European Economic Area. Beyond product-specific approvals, Genoss Co., Ltd. holds ISO 13485 certification, a globally recognized standard for medical device quality management systems. This certification applies to the manufacturer's overall processes, from design and development to production and distribution, reinforcing the quality controls behind products like Elasty Plus 1CC and Monalisa Sub-Q.

The legal status of Monalisa Sub-Q varies significantly by region:

• FDA (USA): Monalisa Sub-Q is not FDA-approved for direct sale or use in the United States. Professionals in the US must be aware of regulatory limitations for non-FDA approved aesthetic injectables.
• UK: As a CE-marked device, Monalisa Sub-Q is generally accepted in the UK, although post-Brexit regulations are continually evolving. Practices should confirm current local requirements.
• GCC (Gulf Cooperation Council): Market access typically requires specific national registrations (e.g., Saudi FDA, UAE Ministry of Health and Prevention). While CE marking often supports these applications, local approval is mandatory.
• LATAM (Latin America): Each country possesses its own regulatory body (e.g., ANVISA in Brazil, COFEPRIS in Mexico). Local registration is essential, often utilizing CE or KFDA documentation as part of the submission.
• APAC (Asia Pacific): Regulations are diverse. Countries like Australia (TGA), Singapore (HSA), and Canada (Health Canada) have independent medical device approval processes. Professionals must verify local import and distribution laws before sourcing for their clinics.

Parallel imports refer to genuine products purchased in one market and imported into another without the consent of the original manufacturer's authorized distributor. While these may appear cost-effective, they carry risks for professionals, including potential lack of traceability, unknown storage and transport conditions (impacting product integrity), and issues with warranty or adverse event reporting. For compliant sourcing, establishing relationships with authorized distributors is crucial. For further insights into reliable sourcing, consult guides such as Dermalax Deep Plus: Wholesale Price Guide for Aesthetic Prof.

When sourcing Monalisa Sub-Q, clinics must perform due diligence on their suppliers. Key documentation to demand includes:

• Certificate of Authenticity (CoA): Issued by the manufacturer or authorized distributor, confirming the product's origin and authenticity.
• Certificate of Analysis: Provides details on product specifications and quality control tests.
• Certificate of Origin: Confirms the country where the product was manufactured.
• Batch Numbers and Expiry Dates: Essential for traceability and product safety management.
• Cold Chain Documentation: Proof of proper temperature-controlled transport, if applicable to the product type.
• Regulatory Registration: Verification that the product is legally registered for import and sale in your specific market.

Sourcing from reputable wholesalers mitigates risks. For instance, ensure your supplier provides equivalent transparency for all products, including lines like Hyaldew or LEXYAL.

Understanding the regulatory landscape of Monalisa Sub-Q is a foundational element for strategic procurement. This knowledge empowers clinics to confidently stock compliant products, ensuring operational integrity and patient safety. Wholesale partners often structure pricing with volume tiers, allowing practices to optimize procurement costs for Monalisa Sub-Q and similar high-demand hyaluronic acid dermal filler products. For example, illustrative wholesale pricing for Monalisa Sub-Q may start around $92.0 per unit, with potential savings of 4% for 11+ units, 5% for 21+, 6% for 31+, and 8% for 51+ units. These tiers are designed to support clinics in managing their inventory efficiently while adhering to regulatory standards.